GI Onc Now Videos
Advertisement
Dr. Cecchini explains how ctDNA was used in this study as well as which methods were used for analyzing ctDNA levels.
Grace-Ann Fasaye discusses the elevated lifetime risk of gastric cancer in patients with CDH1 gene variants.
Dr. Luo describes the performance of the two-fusion gene + α-fetal protein logistic regression model.
Dr. Luo explains the potential benefits of machine learning for patients with hepatocellular carcinoma.
Dr. Arun Nagarajan explains how disparities in testing can affect survival and treatment outcomes for patients with mCRC.
Drs. Uboha and Karasic discuss the benefits and considerations of treating gastric cancer with an anti-CCR8 antibody.
Dr. Faber highlights the implications of increased expression of PDCD1LG2, PDCD1, and HAVCR2 in USC PDAC tumors.
Drs. David H. Ilson and Nataliya Uboha highlight the final OS results of the phase 3 SPOTLIGHT study.
Kai-Keen Shiu, MD, PhD, continues his discussion on neoadjuvant pembrolizumab for patients with colorectal cancer.
Dr. Shiu also discusses how the NEOPRISM-CRC study exceeded its primary endpoint with a high pCR rate.
Dr. Barnell gives an update on the FDA approval of ColoSense and how the test can aid in public health initiatives.
Drs. Ebben and Uboha break down the importance of the QUIC study, a phase 2 investigation of first-line treatment of BTC.
Dr. Eng opines on how the ESOPEC study will alter the treatment paradigm for patients with esophageal/GEJ adenocarcinoma.
Dr. Eng comments on how she approaches treatment considerations and management for her younger patients with colon cancer.
Dr. Eng explains how she makes sense of the stage 4 third-line therapy options to administer to her colon cancer patients.
Dr. Eng shares what the COMMIT study suggest about colon cancer and this study's applicability outside of liver metastasis.
Dr. Eng provides her thoughts on ctDNA upfront, sequential, and combined with NGS testing for patients with colon cancer.
Dr. Aasma Shaukat discusses her recent study on the link between advanced adenoma and long-term risk of colorectal cancer.
Dr. Knox details the early results of the PASS-01 trial, which looked at PDAC signature stratification for treatment.
Richard Finn, MD, of University of California, Los Angeles, highlights 3-year follow-up data from KEYNOTE-966.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.